Molecular Diagnostics Videos

Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor

Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi

Breaking Down Barriers: Feasibility of Internet-based Genetic Testing for Men with Metastatic Prostate Cancer, The GENTleMEN Study -Heather Cheng

Genomic Health Literacy in Treatment Decision-Making for Prostate Cancer - Elisabeth Heath

The Caris Precision Oncology Alliance™ - Chadi Nabhan

How To Read a Genomic Testing Report APCCC 2022 Presentation - Kim Chi

Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron

BRCA1/2 and Beyond - Molecular Diagnostic Testing and Treatments with PARP Inhibitors for mCRPC - Joaquin Mateo

Pembrolizumab in mCRPC Patients with Microsatellite Instability High (MSI-H) Detected by Circulating Tumor DNA - Pedro Barata

The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor

Intersection of Germline and Somatic Testing - Colin Pritchard and Heather Cheng

The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin

The Ethics of Delivering Precision Medicine — Hala Borno

The Prevalence and Impact of Germline Mutations, PROREPAIR-B Trial - Elena Castro

Germline Testing for Patients with Genitourinary Malignancies - Maria Carlo

Genomic Testing - Profiling for Optimization in Cancer Care - Brian T. Helfand

Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer - Colin Pritchard

Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo

Implementing Genetic Testing Into Clinical Practice - Mary-Ellen Taplin

Aiding Cancer Prevention and Treatment by Renaming the BRCA1, BRCA2, and BRCA3 Mutations - Colin Pritchard

Finding the Full Spectrum of Genetic Variants in Advanced Prostate Cancer - Rosalind Eeles

Which Men Need Genetic Counseling and/or Testing? Presentation - Ros Eeles

Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective - Colin Pritchard

The State of the Art on Molecular Characterization of Advanced Prostate Cancer Presentation - Colin Pritchard

Genetic Risk in Prostate Cancer - Jacob Berchuck & Mary-Ellen Taplin

The Association of PBAF Complex Mutations with Overall Survival in Cancer Patients Treated with Checkpoint Inhibitors - Sarah Abou Alaiwi

DNA Repair Defects in Metastatic Prostate Cancer - Elena Castro

Genetic Counseling in Prostate Cancer - Brittany Szymaniak

Molecular Genetic Testing in Prostate Cancer - Wassim Abida

Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro

Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) A Phase II Study - Emmanuel Antonarakis

Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo